Wall Street Wire
G City Reports Strong Q2 2025 Results With 32% FFO Growth and Major Asset Sales
Israeli real estate giant continues operational momentum while executing strategic asset disposal plan
Wall Street Wire
Sponsored company news and issuer-paid coverage. Wall Street Wire articles are paid promotional content; see each article’s disclaimer.
Wall Street Wire
Israeli TV Report Showcases IDF’s “Birds of Prey” Drone System – Technology Traces Back to Duke Robotics
Major Israeli TV Channel Feature Highlights Combat-Tested Drone Technologies Behind Israel’s Groundbreaking Military Operations
Wall Street Wire
BREAKING: Palatin Bags Multi Million Dollar Big Pharma Deal, While Trading at just $5M Market Cap
Palatin Technologies (OTCQB: PTNT.D) announces game-changing partnership with pharmaceutical giant Boehringer Ingelheim worth potentially hundreds of millions. Here’s why PTNTD could be the breakout story of 2025. David Meets Goliath: The Deal That Changes Everything Picture this: You’re a $5.2 million company trading on the
Wall Street Wire
DarioHealth’s Q2 2025 Results Highlight Strategic Revenue Transformation Positioning Company for Sustainable Growth
Second quarter operational discipline and margin expansion demonstrate underlying business strength as company deliberately transitions from one-time contracts to higher-quality recurring revenue streams
Wall Street Wire
The Next $1B Radiotherapy Bet? Why Alpha Tau Medical Should be On Your Radar
The Bottom Line: While trading at a market cap of just around ~$250M, Alpha Tau’s groundbreaking alpha-radiation cancer therapy is showing 90%+ disease control rates and has earned FDA Breakthrough status for brain and skin cancers. With Japan approval expected H2 2025, multiple U.S. trials launching, and
Wall Street Wire
MicroCap Report: Entera Bio is Developing the First Pill to Replace Painful Daily Injections for 200 Million Women
Entera Bio’s EB613 could turn a $3,000/month injection into a simple morning pill, and wall street has given it a price target with ~400% upside (NASDAQ: ENTX)
Wall Street Wire
Is Nuvectis Pharma Poised for a Major Rally as NXP800 Overhang Disappears?
* Latest FINRA data shows 2.6M shares short (over 23% of float) – extremely high short interest now potentially trapped * NXP800 overhang eliminated with final data release, removing primary bear thesis * Recent multi-million dollar block trades suggest institutional accumulation ahead of NXP900 Phase 1b * No major binary events on horizon
Wall Street Wire
RFK Jr.’s Digital Health Revolution: A $161 Billion Opportunity for Smart Investors
Robert F. Kennedy Jr.’s ambitious digital health agenda is poised to reshape America’s healthcare landscape, creating unprecedented opportunities for investors in the rapidly expanding digital therapeutics sector. With his bold declaration that “every American should be wearing a wearable within four years” and the launch of what he
Wall Street Wire
Actelis Networks Secures European Mobile Infrastructure Order Amid Expanding Global Footprint
Actelis Networks (NASDAQ: ASNS) continues to demonstrate commercial momentum with today’s announcement of a new order from a member of a large Pan European Telecom Group for its GigaLine backhaul technology, marking another significant milestone in the company’s rapid expansion across multiple geographic and vertical markets. The latest
Wall Street Wire
Under the Radar Nano Cap Silexion is One to Watch as KRAS-Targeting Heats Up
TL;DR: FDA Breakthrough for Revolution Medicine’s Daraxonrasib and Verastem’s Progress Further Highlight the Excitement Surrounding the KRAS-targeting landscape; Silexion Positioned as an Under-the-Radar Player in the Field as it Advances Unique RNAi Approach Silexion Therapeutics (NASDAQ: SLXN) appears to be approaching a pivotal inflection
Wall Street Wire
Nano-Cap PolyPid Unveils 60-Day GLP-1 Delivery Tech as Pharma Giants Pay Billions for Similar Solutions
After Blockbuster Phase 3 Results in Surgical Infection Prevention, PolyPid Unveils 60-Day GLP-1 Delivery Tech as Pharma Giants Pay Billions for Similar Solutions
Wall Street Wire
Palatin Technologies Unveils Breakthrough Preclinical Data for Oral Obesity Drug PL7737
Company demonstrates rapid weight loss in animal models with potential best-in-class oral MC4R therapy